Article
Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
AIDS research and human retroviruses - 1 Sept 2012
Bethell Richard, Scherer Joseph, Witvrouw Myriam, Paquet Agnes, Coakley Eoin, Hall David
Abstract excerpt
To test tipranavir (TPV) or darunavir (DRV) as treatment options for patients with phenotypic resistance to protease inhibitors (PIs), including lopinavir, saquinavir, atazanavir, and fosamprenavir, the PhenoSense GT database was analyzed for susceptibility to DRV or TPV among PI-resistant isolates. The Monogram Biosciences HIV database (South San Francisco, CA) containing 7775 clinical isolates (2006-2008) not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.